Terms: = Sarcomas AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105 AND Treatment
3 results:
1. [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma].
Guo X; Zhuang RY; Zhou YH; You CL; Zhang Y; Feng F; Shen ZM; Wang WS; Liu Y; Zhang HX; Tong WQ; Lu RK; Luo R
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2428-2434. PubMed ID: 36000371
[No Abstract] [Full Text] [Related]
2. LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/foxa1 axis.
Xie C; Chen B; Wu B; Guo J; Cao Y
Biomed Pharmacother; 2018 Jan; 97():1645-1653. PubMed ID: 29793327
[TBL] [Abstract] [Full Text] [Related]
3. Myxoid liposarcoma. Experience with chemotherapy.
Patel SR; Burgess MA; Plager C; Papadopoulos NE; Linke KA; Benjamin RS
Cancer; 1994 Aug; 74(4):1265-9. PubMed ID: 8055448
[TBL] [Abstract] [Full Text] [Related]
